Compare XPER & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPER | TENX |
|---|---|---|
| Founded | 1990 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.8M | 317.8M |
| IPO Year | 2021 | 2001 |
| Metric | XPER | TENX |
|---|---|---|
| Price | $7.74 | $15.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $11.67 | ★ $29.67 |
| AVG Volume (30 Days) | 418.4K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $448,105,000.00 | N/A |
| Revenue This Year | $4.03 | N/A |
| Revenue Next Year | $8.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.07 | $5.77 |
| 52 Week High | $8.75 | $19.40 |
| Indicator | XPER | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 56.27 |
| Support Level | $7.32 | $12.84 |
| Resistance Level | $8.08 | $16.35 |
| Average True Range (ATR) | 0.35 | 1.24 |
| MACD | -0.06 | 0.19 |
| Stochastic Oscillator | 22.71 | 44.06 |
Xperi Inc is a media and entertainment technology company. Its technologies are integrated into consumer devices, connected cars, and a variety of media platforms globally, enabling audiences to connect with entertainment content in a more intelligent, immersive, and personal way. As its audiences engage with content on the platform, the company operates a cross-screen advertising solution that enables brands to reach millions of engaged consumers across rapidly expanding digital entertainment ecosystem. It operates in one reportable business segment and group its revenue into four categories: Pay-TV, Consumer Electronics, Connected Car and Media Platform. Geographically it operates in U.S. and Canada, Asia Pacific, Europe, Middle East and Africa, and Other countries.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.